AstraZeneca to Buy ZS Pharma for $2.7 Billion in Cash Deal

AstraZeneca Plc, the U.K.’s second-largest drugmaker, agreed to buy ZS Pharma of California for $2.7 billion in cash to gain a potential blockbuster medicine for a deadly condition.

ZS Pharma holders will get $90 per share, London-based AstraZeneca said in a statement. ZS Pharma’s board agreed to the transaction.

Before it's here, it's on the Bloomberg Terminal.